Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
Rhythm Pharmaceuticals presented positive long-term data at the Pediatric Endocrine Society meeting showing pediatric patients treated with setmelanotide sustained BMI reductions of 16.4% over 2.5 years. Separate Phase 3 TRANSCEND trial data showed 71.1% of pediatric patients improved by at least one weight category after one year of treatment, compared to 13.6% for placebo.
Key figures
- Drug Name
- IMCIVREE (setmelanotide)
- Phase Of Trial
- Phase 2
- Bmi z score change
- -1.6
- Pediatric patients n
- 10
- Bmi reduction percent
- -16.4
- Phase 3 participants n
- 67
- Treatment duration years
- 2.5
- Bmi 95th percentile change pp
- -34.2
- Phase 3 responders one category n
- 32
- Phase 3 responders two categories n
- 20
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.